Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2962 in relapsed or refractory myelodysplastic syndromes and dysplastic chronic myelomonocytic leukemia
2025-520786-44-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of azd2962 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 2 more. Started Aug 2025; status: completed.
02
Drugs
azd2962
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2025-520786-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520786-44-00.